Associated tags: GV, Pitango, Chairperson, Research, TCR, Partner, Biomedical Research, Patient, Therapy, Cancer, Pharmaceutical industry, Society
Locations: CHICAGO, MASSACHUSETTS, LOS ANGELES, NY, ILLINOIS, CINCINNATI, WALTHAM, MA, US, BALTIMORE, TEXAS, CHRYSTAL, TX, GEORGETOWN, USA, TD, NEEDHAM, NEW YORK
Public health,
Growth,
Hematology,
Patient,
SVP,
BMS,
Science,
Cancer,
CRISPR Therapeutics,
Baylor College of Medicine,
Pleasure,
Merrimack Pharmaceuticals,
Therapy,
Drug development,
TCR,
Tropical medicine,
Pharmaceutical industry Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization.
Key Points:
- Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization.
- “We are excited to welcome Chrystal to TScan at this critical time as we continue to progress both clinical-stage programs in heme malignancies and solid tumors.
- “I look forward to working with Chrystal as we strive to realize the full potential of our pipeline.
- Prior to joining TScan, Dr. Louis was the SVP of hematology clinical development at Zentalis Pharmaceuticals.
WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 2:15 p.m. Eastern Time.
Key Points:
- WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 2:15 p.m. Eastern Time.
- A webcast of the presentation will be available on the “ Events and Presentations ” section of the Company’s website at ir.tscan.com .
- An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
Tandem,
AML,
Neoplasm,
FDA,
Quality of life,
Food,
Data,
AACR,
Histocompatibility,
Society,
MDS,
Transplant,
Therapy,
Food and Drug Administration,
Patient,
Clinical trial,
TCR,
IND,
KOL,
MAGE-A1,
Cancer,
Pharmaceutical industry The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.
Key Points:
- The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.
- With recent FDA clearance of our INDs for TSC-201-B0702 and TSC-204-A0101, we now have six TCR-Ts cleared for clinical development.
- Data showed that all eight (100%) treatment-arm patients were free from relapse, including four patients with follow-up beyond ten months.
- The Company will present two “Trials in Progress” poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.
Retrieved on:
Wednesday, February 28, 2024
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference being held at the Marriott Copley Place in Boston on Wednesday, March 6, 2024 at 9:10 a.m. Eastern Time.
Key Points:
- WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference being held at the Marriott Copley Place in Boston on Wednesday, March 6, 2024 at 9:10 a.m. Eastern Time.
- A webcast of the panel discussion will be available on the “ Events and Presentations ” section of the Company’s website at ir.tscan.com .
- An archived replay of the webcast will be available on the Company’s website for 30 days following the event.
Retrieved on:
Monday, February 26, 2024
AML,
ALL,
Chimera,
Syndrome,
HCT,
Quality of life,
Safety,
Society,
MDS,
Therapy,
Immunosuppression,
Patient,
Acute leukemia,
MRD,
TCR,
Transplant,
Acute myeloid leukemia,
KOL,
DNA,
Cancer,
Medical device “We are excited to report updated data from our heme program, with eight patients across our treatment arms and six patients in our control arm.
Key Points:
- “We are excited to report updated data from our heme program, with eight patients across our treatment arms and six patients in our control arm.
- We remain encouraged to see that no relapses have occurred to date in treated patients, four of whom have been on the study for over ten months.
- Unfortunately, roughly 40% of patients relapse following HCT, at which point there are limited treatment options and a poor prognosis.
- A replay will be made available on the “ Events and Presentations ” section of the Company’s investor relations website at ir.tscan.com .
Retrieved on:
Wednesday, February 14, 2024
Translational medicine,
Senior,
AML,
ALL,
Medicine,
Syndrome,
HCT,
Risk,
Society,
MDS,
Therapy,
Patient,
Acute leukemia,
TCR,
Transplant,
Acute myeloid leukemia,
KOL,
Cancer WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®) on Monday, February 26, 2024, at 8:00 a.m. ET.
Key Points:
- ET.
- The event will provide an in-depth review of the oral presentation related to TScan’s ongoing Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) ( NCT05473910 ).
- The Company will also discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse.
- Shrikanta Chattopadhyay, M.D., M.M.Sc., Senior Vice President of Medical and Translational Medicine, TScan Therapeutics
Retrieved on:
Tuesday, February 6, 2024
Rubius,
Drug,
Translational research,
Patient,
Pediatrics,
Medicine,
Therapy,
University,
TCR,
Acquisition,
Amgen,
Cancer,
Onyx Pharmaceuticals,
Nursing Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry.
Key Points:
- Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry.
- “We are pleased to welcome Dawn to TScan at such an exciting time in the Company’s evolution,” said Debora Barton, M.D., Chief Medical Officer.
- “Her expertise in cell and gene therapy clinical development and experience with regulatory interactions, most recently at ElevateBio, will be crucial as we advance our clinical-stage pipeline across heme malignancies and solid tumors.
- from Drexel University College of Medicine, and an M.S., Clinical and Translational Research, from the University of Cincinnati.
Commonwealth,
Patient,
Therapy,
Heme,
TCR,
Certified Public Accountant,
New England Baptist Hospital,
Treasurer,
Cancer,
Sale,
IPO,
Acer,
Genzyme Mr. Amello, a senior finance executive, brings to TScan nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry.
Key Points:
- Mr. Amello, a senior finance executive, brings to TScan nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry.
- “We are pleased to welcome Jason to TScan at such an exciting time as we continue to make significant progress across both our heme and solid tumor programs, with multiple important milestones on the horizon,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
- “Jason’s corporate experience, having held several prior appointments as Chief Financial Officer, comes at the right time for us, as we continue to strategically advance our clinical-stage programs.
- From 2000 to 2011, Mr. Amello held multiple finance leadership positions at Genzyme Corporation (acquired by Sanofi AG), including Senior Vice President and Chief Accounting Officer.
Retrieved on:
Thursday, January 18, 2024
Syndrome,
Patient,
Therapy,
Transplant,
MDS,
TCR,
Acute myeloid leukemia,
ALL,
Society,
Cancer,
Acute leukemia,
Tandem,
HCT,
AML,
Abstract (summary) WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), being held from February 21-24, 2024, in San Antonio, Texas and online. The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) (NCT05473910). The following abstract was selected by the Tandem Meetings to receive a Best Abstracts Award.
Key Points:
- WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), being held from February 21-24, 2024, in San Antonio, Texas and online.
- The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) ( NCT05473910 ).
- The following abstract was selected by the Tandem Meetings to receive a Best Abstracts Award.
- Location: Stars at Night B2 & B3 (Ballroom Level, Henry B. González Convention Center)
A copy of the presentation materials will be added to the “ Events and Presentations ” section of the Company’s Investor Relations website at ir.tscan.com once presentations have concluded.
Retrieved on:
Thursday, January 4, 2024
Patient,
Food,
Acute leukemia,
Neoplasm,
Immunotherapy,
PRAME,
Amgen,
IND,
Collection,
MRD,
TCR,
FDA,
Antigen,
HLA,
Trial of the century,
Society,
Therapy,
MDS,
Infrared spectroscopy correlation table,
Cancer,
Disclosure,
ASH,
Annual general meeting,
HCT,
MAGE-C2,
Syndrome,
Poster,
Safety,
ALL,
Acute myeloid leukemia,
C2,
AML,
MAGE-A1,
Food and Drug Administration,
HPV16,
SITC,
Pharmaceutical industry WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2024 clinical pipeline plans and highlighted recent corporate achievements.
Key Points:
- Additionally, we submitted INDs for two additional TCRs in December and the 30-day review period with the FDA is ongoing.
- Plans to complete Phase 1 dosing and report clinical and translational data in 2024, and two-year relapse data in 2025.
- Initiated Phase 1 solid tumor clinical study and expects to dose the first patient in the first quarter of 2024.
- Plans to continue to build ImmunoBank with additional IND filings throughout 2024.
